...
search icon
kzia-img

Kazia Therapeutics Ltd ADR, Common Stock

KZIA

NAQ

$13.03

-$0.22

(-1.66%)

1D
Industry: Biotechnology Sector: Health Care

Analyst Forecast

Price Chart

Key Metrics

Market Cap info-icon
This is a company’s total value as determined by the stock market. It is calculated by multiplying the total number of a company's outstanding shares by the current market price of one share.
$22.14M
P/E Ratio info-icon
This is the ratio of a security’s current share price to its earnings per share. This ratio determines the relative value of a company’s share.
0
Volume info-icon
This is the total number of shares traded during the most recent trading day.
334.69K
Avg Volume info-icon
This is the average number of shares traded during the most recent 30 days.
0
Dividend Yield info-icon
This ratio shows how much income you earn in dividend payouts per year for every dollar invested in the stock (or the stock’s annual dividend payment expressed as a percentage of its current price).
0.00%
Beta info-icon
This measures the expected move in a stock’s price relative to movements in the overall market. The market, such as the S&P 500 Index, has a beta of 1.0. If a stock has a Beta greater (or lower) than 1.0, it suggests that the stock is more (or less) volatile than the broader market.
1.72
52-week Range info-icon
This shows the range of the stock’s price between the 52-week high (the highest price of the stock for the past 52 weeks) and the 52-week low (the lowest price of the stock for the past 52 weeks).
$2.86 L
$23.6 H
$13.03

About Kazia Therapeutics Ltd ADR, Common Stock

Kazia Therapeutics Limited, together with its subsidiaries, operates as an oncology-focused biotechnology company in Israel. The company's lead development candidate is paxalisib, a small molecule, brain-penetrant inhibitor of the phosphoinositide-3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) pathway, which is in Phase II/III clinical trial for the treatment of glioblastoma; in Phase II trial to treat isocitrate dehydrogenase-mutant glioma, primary central nervous system (CNS) lymphoma, diffuse intrinsic pontine glioma, and brain metastases; and in pre-clinical studies to treat triple-negative breast cancer, as well as for the treatment of atypical rhabdoid/teratoid tumors. It also develops EVT801, a small-molecule selective inhibitor of vascular endothelial growth factor receptor 3 that is in Phase I clinical trial to treat advanced solid tumors and ovarian cancer. The company has collaborations with the Australian and New Zealand Children's Haematology/Oncology Group, Genentech Inc., Global Coalition for Adaptive Research, Vivesto AB, Simcere Pharmaceutical Group Ltd, Evotec SE, Sovargen Co., Ltd, and QIMR Berghofer Medical Research Institute. The company was formerly known as Novogen Limited and changed its name to Kazia Therapeutics Limited in November 2017. Kazia Therapeutics Limited was incorporated in 1994 and is based in Sydney, Australia. more

Industry: BiotechnologySector: Health Care

Returns

Time FrameKZIASectorS&P500
1-Week Return26.82%-1.63%0.06%
1-Month Return74.67%6.88%1.25%
3-Month Return65.39%12.84%5.39%
6-Month Return149.86%16.35%14.81%
1-Year Return-40.86%5.68%12.55%
3-Year Return-57.85%12.02%71.17%
5-Year Return-97.28%37.8%85.04%
10-Year Return-97.04%116.05%227.21%

Financials

Jun '21Jun '22Jun '23Jun '24Jun '255YR TREND
Total Revenue15.18M10.00K555.002.31M42.00K[{"date":"2021-06-30","value":100,"profit":true},{"date":"2022-06-30","value":0.07,"profit":true},{"date":"2023-06-30","value":"-","profit":true},{"date":"2024-06-30","value":15.2,"profit":true},{"date":"2025-06-30","value":0.28,"profit":true}]
Cost of Revenue-----[{"date":"2021-06-30","value":"-","profit":true},{"date":"2022-06-30","value":"-","profit":true},{"date":"2023-06-30","value":"-","profit":true},{"date":"2024-06-30","value":"-","profit":true},{"date":"2025-06-30","value":"-","profit":true}]
Gross Profit15.18M10.00K555.002.31M42.00K[{"date":"2021-06-30","value":100,"profit":true},{"date":"2022-06-30","value":0.07,"profit":true},{"date":"2023-06-30","value":"-","profit":true},{"date":"2024-06-30","value":15.2,"profit":true},{"date":"2025-06-30","value":0.28,"profit":true}]
Gross Margin100.00%100.00%100.00%100.00%100.00%[{"date":"2021-06-30","value":100,"profit":true},{"date":"2022-06-30","value":100,"profit":true},{"date":"2023-06-30","value":100,"profit":true},{"date":"2024-06-30","value":100,"profit":true},{"date":"2025-06-30","value":100,"profit":true}]
Operating Expenses21.56M25.41M24.12M30.77M14.26M[{"date":"2021-06-30","value":70.06,"profit":true},{"date":"2022-06-30","value":82.58,"profit":true},{"date":"2023-06-30","value":78.4,"profit":true},{"date":"2024-06-30","value":100,"profit":true},{"date":"2025-06-30","value":46.34,"profit":true}]
Operating Income(6.38M)(25.40M)(24.12M)(28.46M)(14.22M)[{"date":"2021-06-30","value":-637600000,"profit":false},{"date":"2022-06-30","value":-2539900000,"profit":false},{"date":"2023-06-30","value":-2412396900,"profit":false},{"date":"2024-06-30","value":-2846200000,"profit":false},{"date":"2025-06-30","value":-1421700000,"profit":false}]
Total Non-Operating Income/Expense(2.49M)19.09K3.43M1.43M(8.16M)[{"date":"2021-06-30","value":-72.42,"profit":false},{"date":"2022-06-30","value":0.56,"profit":true},{"date":"2023-06-30","value":100,"profit":true},{"date":"2024-06-30","value":41.51,"profit":true},{"date":"2025-06-30","value":-237.69,"profit":false}]
Pre-Tax Income(8.90M)(25.38M)(20.74M)(27.05M)(22.45M)[{"date":"2021-06-30","value":-890400000,"profit":false},{"date":"2022-06-30","value":-2538200000,"profit":false},{"date":"2023-06-30","value":-2073627200,"profit":false},{"date":"2024-06-30","value":-2704900000,"profit":false},{"date":"2025-06-30","value":-2244800000,"profit":false}]
Income Taxes(484.00K)(368.00K)(271.09K)(271.00K)(1.75M)[{"date":"2021-06-30","value":-48400000,"profit":false},{"date":"2022-06-30","value":-36800000,"profit":false},{"date":"2023-06-30","value":-27109200,"profit":false},{"date":"2024-06-30","value":-27100000,"profit":false},{"date":"2025-06-30","value":-174600000,"profit":false}]
Income After Taxes(8.42M)(25.01M)(20.47M)(26.78M)(20.70M)[{"date":"2021-06-30","value":-842000000,"profit":false},{"date":"2022-06-30","value":-2501400000,"profit":false},{"date":"2023-06-30","value":-2046518000,"profit":false},{"date":"2024-06-30","value":-2677800000,"profit":false},{"date":"2025-06-30","value":-2070200000,"profit":false}]
Income From Continuous Operations(8.42M)(24.65M)(20.47M)(26.78M)(20.70M)[{"date":"2021-06-30","value":-842200000,"profit":false},{"date":"2022-06-30","value":-2464781500,"profit":false},{"date":"2023-06-30","value":-2046518000,"profit":false},{"date":"2024-06-30","value":-2677800000,"profit":false},{"date":"2025-06-30","value":-2070200000,"profit":false}]
Income From Discontinued Operations-----[{"date":"2021-06-30","value":"-","profit":true},{"date":"2022-06-30","value":"-","profit":true},{"date":"2023-06-30","value":"-","profit":true},{"date":"2024-06-30","value":"-","profit":true},{"date":"2025-06-30","value":"-","profit":true}]
Net Income(8.42M)(25.01M)(20.47M)(26.78M)(20.70M)[{"date":"2021-06-30","value":-842000000,"profit":false},{"date":"2022-06-30","value":-2501400000,"profit":false},{"date":"2023-06-30","value":-2046518000,"profit":false},{"date":"2024-06-30","value":-2677800000,"profit":false},{"date":"2025-06-30","value":-2070200000,"profit":false}]
EPS (Diluted)-----[{"date":"2021-06-30","value":"-","profit":true},{"date":"2022-06-30","value":"-","profit":true},{"date":"2023-06-30","value":"-","profit":true},{"date":"2024-06-30","value":"-","profit":true},{"date":"2025-06-30","value":"-","profit":true}]

Ratios

Liquidity

These ratios help you determine the liquidity of the company. Higher is better.

KZIA
Cash Ratio 0.31
Current Ratio 0.35

Asset Efficiency

These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.

KZIA
ROA (LTM) -64.28%
ROE (LTM) -3891.64%

Liabilities

These ratios help you understand the company's liabilities, gauging the riskiness of the investment.

KZIA
Debt Ratio Lower is generally better. Negative is bad. 2.37
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. -1.37

Valuation

These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.

KZIA
Trailing PE NM
Forward PE NM
P/S (TTM) 77.75
P/B 3.09
Price/FCF NM
EV/R 461.86
EV/Ebitda NM

FAQs

What is Kazia Therapeutics Ltd ADR share price today?

Kazia Therapeutics Ltd ADR (KZIA) share price today is $13.03

Can Indians buy Kazia Therapeutics Ltd ADR shares?

Yes, Indians can buy shares of Kazia Therapeutics Ltd ADR (KZIA) on Vested. To buy Kazia Therapeutics Ltd ADR from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in KZIA stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.

Can Fractional shares of Kazia Therapeutics Ltd ADR be purchased?

Yes, you can purchase fractional shares of Kazia Therapeutics Ltd ADR (KZIA) via the Vested app. You can start investing in Kazia Therapeutics Ltd ADR (KZIA) with a minimum investment of $1.

How to invest in Kazia Therapeutics Ltd ADR shares from India?

You can invest in shares of Kazia Therapeutics Ltd ADR (KZIA) via Vested in three simple steps:

  • Click on Sign Up or Invest in KZIA stock at the top of this page
  • Breeze through our fully digital and secure KYC process and open your US Brokerage account in a few minutes
  • Transfer USD funds to your US Brokerage account and start investing in Kazia Therapeutics Ltd ADR shares
What is Kazia Therapeutics Ltd ADR 52-week high and low stock price?

The 52-week high price of Kazia Therapeutics Ltd ADR (KZIA) is $23.6. The 52-week low price of Kazia Therapeutics Ltd ADR (KZIA) is $2.86.

What is Kazia Therapeutics Ltd ADR price-to-book (P/B) ratio?

The price-to-book (P/B) ratio of Kazia Therapeutics Ltd ADR (KZIA) is 3.09

What is the Market Cap of Kazia Therapeutics Ltd ADR?

The market capitalization of Kazia Therapeutics Ltd ADR (KZIA) is $22.14M

What is Kazia Therapeutics Ltd ADR’s stock symbol?

The stock symbol (or ticker) of Kazia Therapeutics Ltd ADR is KZIA

Signup to access all features and start your US investing journey!

  • Open your account in minutes
  • Take your portfolio global, starting at just $1
Get started

Add ticker to compare

Scroll to Top